RecruitingNCT00001971
Rare condition
Hepatitis delta
20
studies recruiting now
as of 7 Sept 2026
123
studies registered in total
as of 7 Sept 2026
19
countries with a recruiting site
as of 7 Sept 2026
30 Mar 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT07096193
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
RecruitingPhase 3NCT07200908
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
RecruitingPhase 2 / Phase 3NCT07454837
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
RecruitingPhase 3NCT07499544
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 20 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Hepatitis delta study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Hepatitis delta
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
2 approved treatments and 10 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Bulevirtide (Hepcludextm)Approved: Bulevirtide Acetate (Hepcludex)
Phase 3Lonafarnib (Zokinvy)
Phase 3Peginterferon Alfa-2b (Peg-intron)
Phase 3Peginterferon Lambda-1a
Phase 3Ritonavir (Norvir)
Phase 3Tenofovir Anhydrous
Phase 3Peginterferon Alfa-2a (Pegasys)
Phase 2Hepalatide
Phase 2Tobevibart
+ 2 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).